89Zr-DFO*Trastuzumab

N/A

Report date: 2025/10/20 14:27:18

Base Information

Drug Name89Zr-DFO*Trastuzumab

Drug Alias Name89Zr-labeled trastuzumab89Zr-trastuzumab89Zr-DFO*-Trastuzumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4]

Mechanisms of ActionIonising radiation emittersRadionuclide imaging enhancersAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancerStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAstrazeneca Plc

China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc

Inactive CompaniesN/A

Active IndicationsMetastatic breast cancerStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A